Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
McKesson
Farmers Insurance
Cantor Fitzgerald
Mallinckrodt
AstraZeneca

Generated: September 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,458,836

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,458,836 protect, and when does it expire?

Patent 6,458,836 protects RESCULA and is included in one NDA.

This patent has twenty-one patent family members in eighteen countries.

Summary for Patent: 6,458,836
Title: Treatment of ocular hypertension and glaucoma
Abstract:Disclosed is treatment of ocular hypertension and glaucoma by long-term therapy with a prostaglandin related compound for eliminating or reducing potential iridic pigmentation. Composition useful for the treatment, and use of the prostaglandin related compound for producing the composition are also disclosed.
Inventor(s): Ueno; Ryuji (Potomac, MD)
Assignee: Sucampo, A.G. (Zug, CH)
Application Number:09/900,021
Patent Claim Types:
see list of patent claims
Use; Compound; Process;

Drugs Protected by US Patent 6,458,836

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sucampo Pharma Llc RESCULA unoprostone isopropyl SOLUTION/DROPS;OPHTHALMIC 021214-001 Aug 3, 2000 DISCN Yes No ➤ Sign Up ➤ Sign Up THE LONG TERM TREATMENT OF PROPHYLACTIC MANAGEMENT OF OCULAR HYPERTENSION AND GLAUCOMA ➤ Sign Up
Sucampo Pharma Llc RESCULA unoprostone isopropyl SOLUTION/DROPS;OPHTHALMIC 021214-001 Aug 3, 2000 DISCN Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING OCULAR HYPERTENSION ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 6,458,836

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 029818 ➤ Sign Up
Australia 2001241143 ➤ Sign Up
Australia 4114301 ➤ Sign Up
Brazil 0109192 ➤ Sign Up
Canada 2402597 ➤ Sign Up
China 100506232 ➤ Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Johnson and Johnson
QuintilesIMS
Chinese Patent Office
Fuji
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.